Bevacizumab plus docetaxel and cisplatin for metastatic breast cancer

A pilot phase II study

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Bevacizumab is a monoclonal antibody that prevents angiogenesis by inhibiting vascular endothelial growth factor (VEGF) activity. Clinically, it has been used to treat a diverse range of cancer types. In this pilot phase II study, we investigated the efficacy and safety profiles of bevacizumab in combination with docetaxel plus cisplatin for patients with advanced HER2-negative metastatic breast cancer. Patients and Methods: Between 2005 and 2008, 20 patients with advanced breast cancer were recruited from the Taipei Medical University Hospital. Bevacizumab was administered every two weeks in a 12- cycle treatment with docetaxel plus cisplatin. The primary end-point for this study was the overall response rate. The secondary end-points were progression-free survival and the safety profiles of the combined therapy. Results: The average number of treatment cycles was 10.5 with a response rate of 80%. Neutropenia and neuropathy were the most commonly observed adverse events. Seven patients achieved complete remission and nine patients achieved partial remission. For the overall patient group in this study, the median time-toprogression and overall survival were 28.0 weeks and 52 weeks, respectively. The median time-to-progression and overall survival for the 10 patients that completed all 12 cycles of treatment were 64.0 weeks and 80 weeks, respectively. In one patient, a very rapid reduction in the level of breast cancer lung metastases was observed one week post-treatment. Conclusion: Based on this pilot study, bevacizumab in combination with docetaxel and cisplatin is likely to be an effective treatment option for metastatic breast cancer that warrants further study.

Original languageEnglish
Pages (from-to)5501-5506
Number of pages6
JournalAnticancer Research
Volume32
Issue number12
Publication statusPublished - Dec 2012

Fingerprint

docetaxel
Cisplatin
Breast Neoplasms
Therapeutics
Safety
Survival
Bevacizumab
Neutropenia
Vascular Endothelial Growth Factor A
Disease-Free Survival

Keywords

  • Bevacizumab
  • Breast cancer
  • Cisplatin
  • Docetaxel
  • HER2-negative
  • Metastatic

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{548e9a2cfd8b4843b5a394479b9a0045,
title = "Bevacizumab plus docetaxel and cisplatin for metastatic breast cancer: A pilot phase II study",
abstract = "Background: Bevacizumab is a monoclonal antibody that prevents angiogenesis by inhibiting vascular endothelial growth factor (VEGF) activity. Clinically, it has been used to treat a diverse range of cancer types. In this pilot phase II study, we investigated the efficacy and safety profiles of bevacizumab in combination with docetaxel plus cisplatin for patients with advanced HER2-negative metastatic breast cancer. Patients and Methods: Between 2005 and 2008, 20 patients with advanced breast cancer were recruited from the Taipei Medical University Hospital. Bevacizumab was administered every two weeks in a 12- cycle treatment with docetaxel plus cisplatin. The primary end-point for this study was the overall response rate. The secondary end-points were progression-free survival and the safety profiles of the combined therapy. Results: The average number of treatment cycles was 10.5 with a response rate of 80{\%}. Neutropenia and neuropathy were the most commonly observed adverse events. Seven patients achieved complete remission and nine patients achieved partial remission. For the overall patient group in this study, the median time-toprogression and overall survival were 28.0 weeks and 52 weeks, respectively. The median time-to-progression and overall survival for the 10 patients that completed all 12 cycles of treatment were 64.0 weeks and 80 weeks, respectively. In one patient, a very rapid reduction in the level of breast cancer lung metastases was observed one week post-treatment. Conclusion: Based on this pilot study, bevacizumab in combination with docetaxel and cisplatin is likely to be an effective treatment option for metastatic breast cancer that warrants further study.",
keywords = "Bevacizumab, Breast cancer, Cisplatin, Docetaxel, HER2-negative, Metastatic",
author = "Tai, {Cheng Jeng} and Chen, {Ching Shyang} and Hung, {Chin Sheng} and Kuo, {Li Jen} and Wei, {Po Li} and Chiou, {Jeng Feng} and Hsu, {Chung Huei} and Chiou, {Hung Yi} and Wu, {Chih Hsiung}",
year = "2012",
month = "12",
language = "English",
volume = "32",
pages = "5501--5506",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "12",

}

TY - JOUR

T1 - Bevacizumab plus docetaxel and cisplatin for metastatic breast cancer

T2 - A pilot phase II study

AU - Tai, Cheng Jeng

AU - Chen, Ching Shyang

AU - Hung, Chin Sheng

AU - Kuo, Li Jen

AU - Wei, Po Li

AU - Chiou, Jeng Feng

AU - Hsu, Chung Huei

AU - Chiou, Hung Yi

AU - Wu, Chih Hsiung

PY - 2012/12

Y1 - 2012/12

N2 - Background: Bevacizumab is a monoclonal antibody that prevents angiogenesis by inhibiting vascular endothelial growth factor (VEGF) activity. Clinically, it has been used to treat a diverse range of cancer types. In this pilot phase II study, we investigated the efficacy and safety profiles of bevacizumab in combination with docetaxel plus cisplatin for patients with advanced HER2-negative metastatic breast cancer. Patients and Methods: Between 2005 and 2008, 20 patients with advanced breast cancer were recruited from the Taipei Medical University Hospital. Bevacizumab was administered every two weeks in a 12- cycle treatment with docetaxel plus cisplatin. The primary end-point for this study was the overall response rate. The secondary end-points were progression-free survival and the safety profiles of the combined therapy. Results: The average number of treatment cycles was 10.5 with a response rate of 80%. Neutropenia and neuropathy were the most commonly observed adverse events. Seven patients achieved complete remission and nine patients achieved partial remission. For the overall patient group in this study, the median time-toprogression and overall survival were 28.0 weeks and 52 weeks, respectively. The median time-to-progression and overall survival for the 10 patients that completed all 12 cycles of treatment were 64.0 weeks and 80 weeks, respectively. In one patient, a very rapid reduction in the level of breast cancer lung metastases was observed one week post-treatment. Conclusion: Based on this pilot study, bevacizumab in combination with docetaxel and cisplatin is likely to be an effective treatment option for metastatic breast cancer that warrants further study.

AB - Background: Bevacizumab is a monoclonal antibody that prevents angiogenesis by inhibiting vascular endothelial growth factor (VEGF) activity. Clinically, it has been used to treat a diverse range of cancer types. In this pilot phase II study, we investigated the efficacy and safety profiles of bevacizumab in combination with docetaxel plus cisplatin for patients with advanced HER2-negative metastatic breast cancer. Patients and Methods: Between 2005 and 2008, 20 patients with advanced breast cancer were recruited from the Taipei Medical University Hospital. Bevacizumab was administered every two weeks in a 12- cycle treatment with docetaxel plus cisplatin. The primary end-point for this study was the overall response rate. The secondary end-points were progression-free survival and the safety profiles of the combined therapy. Results: The average number of treatment cycles was 10.5 with a response rate of 80%. Neutropenia and neuropathy were the most commonly observed adverse events. Seven patients achieved complete remission and nine patients achieved partial remission. For the overall patient group in this study, the median time-toprogression and overall survival were 28.0 weeks and 52 weeks, respectively. The median time-to-progression and overall survival for the 10 patients that completed all 12 cycles of treatment were 64.0 weeks and 80 weeks, respectively. In one patient, a very rapid reduction in the level of breast cancer lung metastases was observed one week post-treatment. Conclusion: Based on this pilot study, bevacizumab in combination with docetaxel and cisplatin is likely to be an effective treatment option for metastatic breast cancer that warrants further study.

KW - Bevacizumab

KW - Breast cancer

KW - Cisplatin

KW - Docetaxel

KW - HER2-negative

KW - Metastatic

UR - http://www.scopus.com/inward/record.url?scp=84872660072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872660072&partnerID=8YFLogxK

M3 - Article

VL - 32

SP - 5501

EP - 5506

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 12

ER -